ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
내분비 치료제 시장 규모는 향후 수년간 약간의 성장이 예상됩니다. 2029년에 연평균 성장률(CAGR)은 0.2%를 나타낼 것으로 예측되고 263억 7,000만 달러로 성장할 전망입니다. 예측 기간 동안의 성장은 당뇨병 환자 증가, 내분비 장애 유병률 상승, 호르몬 불균형 청소년 증가, 비만율 상승 등에 기인할 수 있습니다. 예측 기간의 주요 동향에는 기술적 발전, 고급 약물 전달 시스템 도입, 디지털 헬스 솔루션 통합, 정밀 의학, 복합 요법이 포함됩니다.
향후 5년간 0.2% 성장률 전망은 해당 시장에 대한 이전 추정치 대비 0.3% 소폭 하향 조정된 수치입니다. 이 같은 하향 조정은 주로 미국과 타국 간 관세 영향 때문입니다. 무역 제한 조치는 프랑스와 인도에서 수입되는 재조합 인슐린 유사체 및 갑상선 치료제 유효 성분의 가격 상승을 유발하여 미국 내 호르몬 치료 접근성을 저해할 수 있으며, 이는 당뇨병 관리 지연과 만성 질환 치료 비용 증가로 이어질 수 있습니다. 상호 관세 부과와 무역 긴장 및 제한 강화로 인한 전 세계 경제 및 무역에 대한 부정적 영향으로 그 효과는 더욱 광범위하게 나타날 것입니다.
내분비 질환의 증가하는 유병률은 내분비 치료제 시장을 촉진하고 있습니다. 내분비 질환은 내분비계에 영향을 미치는 장애로, 호르몬 생산 또는 조절의 불균형을 초래하여 정상적인 신체 기능을 방해합니다. 내분비 질환 유병률 증가 요인에는 생활 방식 변화, 인구 고령화, 진단 방법 개선 등이 포함되며, 이로 인해 해당 질환의 인식도와 발생률이 높아졌습니다. 내분비 치료제는 호르몬 수치 조절, 내분비선 기능 장애 치료, 호르몬 균형 회복을 통해 이러한 질환을 관리함으로써 건강 결과를 개선하도록 설계되었습니다. 예를 들어, 2023년 5월 미국 국립의학도서관은 미국 내 약 1,300만 명(인구의 약 4.78%)이 진단되지 않은 내분비 장애를 앓고 있으며, 갑상선 질환이 가장 흔한 질환 중 하나로 내분비 진료에서 치료받는 환자의 30-40%를 차지한다고 보고했습니다. 이러한 내분비 질환의 증가하는 유병률은 내분비 치료제에 대한 수요를 상당하게 촉진하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 내분비 치료제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 내분비 치료제 시장 : 성장률 분석
세계의 내분비 치료제 시장 실적 : 규모와 성장(2019-2024년)
세계의 내분비 치료제 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 내분비 치료제 : 총 잠재시장 규모(TAM)
제6장 시장 세분화
세계의 내분비 치료제 시장 : 적응증별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
갑상선 기능 항진증
갑상선 기능 저하증
당뇨병
다낭성 난소 증후군
성장 호르몬 장애
뇌하수체 장애
기타 적응증
세계의 내분비 치료제 시장 : 치료 영역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
당뇨병약
갑상선 호르몬 치료제
인간 성장 호르몬
테스토스테론 대체 요법
기타 치료 영역
세계의 내분비 치료제 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
온라인 약국
소매 약국
세계의 내분비 치료제 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
외래수술센터(ASC)
기타 최종 사용자
세계의 내분비 치료제 시장, 갑상선 기능 항진증 유형별 세분화 : 분석과 예측(2019-2024년, 2024-2029년, 2034년)
항갑상선 치료제
방사성 요오드 요법
베타 차단제
세계의 내분비 치료제 시장, 갑상선 기능 저하증 유형별 세분화 : 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 내분비 치료제 시장, 기타 적응증 유형별 세분화 : 분석과 예측(2019-2024년, 2024-2029년, 2034년)
부신 장애
골다공증
부갑상선 장애
남성 호르몬 불균형
제7장 지역별, 국가별 분석
세계의 내분비 치료제 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 내분비 치료제 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
내분비 치료제 시장 : 경쟁 구도
내분비 치료제 시장 : 기업 프로파일
Johnson & Johnson Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Bayer Aktiengesellschaft : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis International AG : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Sanofi SA
AstraZeneca plc
Abbott Laboratories
GlaxoSmithKline plc
Takeda Pharmaceutical Company Limited
Eli Lilly and Company
Amgen Inc.
Novo Nordisk A/S
Biocon Limited
Boehringer Ingelheim International GmbH
Mylan NV
Sandoz International GmbH
Ipsen Pharma
Ferring Pharmaceuticals Inc.
Endocrine Pharma Private Limited
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
내분비 치료제 시장(2029년) : 새로운 기회를 제공하는 국가
내분비 치료제 시장(2029년) : 새로운 기회를 제공하는 부문
내분비 치료제 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
HBR
영문 목차
영문목차
Endocrinology drugs are pharmaceutical treatments designed to manage and regulate disorders associated with the endocrine system, which includes glands such as the thyroid, pancreas, and adrenal glands. These drugs are used to treat conditions such as diabetes, thyroid disorders, growth hormone deficiencies, and hormonal imbalances, aiming to restore normal hormonal levels and improve the overall function of the endocrine system.
The primary conditions treated with endocrinology drugs include hyperthyroidism, hypothyroidism, diabetes, polycystic ovarian syndrome, growth hormone disorders, and pituitary gland disorders, among others. Hyperthyroidism, for example, is marked by an overproduction of thyroid hormones, causing symptoms such as weight loss, rapid heartbeat, and anxiety. Key therapy areas include diabetes medications, thyroid hormone disorder treatments, human growth hormone, testosterone replacement therapy, and others. These drugs are distributed through various channels, such as hospital pharmacies, online pharmacies, and retail pharmacies, and are used by a range of end users, including hospitals, ambulatory surgical centers, and more.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.
The endocrinology drugs market research report is one of a series of new reports from The Business Research Company that provides endocrinology drugs market statistics, including endocrinology drugs industry global market size, regional shares, competitors with an endocrinology drugs market share, detailed endocrinology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the endocrinology drugs industry. This endocrinology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The endocrinology drugs market size has declined marginally in recent years. It will grow from $26.29 billion in 2024 to $26.2 billion in 2025 at a compound annual growth rate (CAGR) of -0.3%. The growth in the historic period can be attributed to increasing prevalence of diabetes globally, increasing government initiatives, increasing healthcare expenditure, increasing prevalence of adrenal gland disorders, a rise in demand for insulin analogs, and growth in the number of endocrinologists.
The endocrinology drugs market size is expected to see marginal growth in the next few years. It will grow to $26.37 billion in 2029 at a compound annual growth rate (CAGR) of 0.2%. The growth in the forecast period can be attributed to a growing diabetic population, increasing prevalence of endocrine disorders, a growing number of adolescents with hormonal imbalances, and rising obesity rates. Major trends in the forecast period include technological advancements, adoption of advanced drug delivery systems, integration of digital health solutions, precision medicine, and combination therapies.
The forecast of 0.2% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade restrictions could hinder U.S. hormone therapy access by inflating prices of recombinant insulin analogs and thyroid medication active pharmaceutical ingredients imported from France and India, resulting in delayed diabetes management and higher chronic disease treatment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rising prevalence of endocrine diseases is driving the growth of the endocrinology drugs market. Endocrine diseases are disorders that affect the endocrine system, leading to imbalances in hormone production or regulation, which disrupt normal bodily functions. Factors contributing to the increasing prevalence of endocrine diseases include lifestyle changes, an aging population, and improvements in diagnostic methods, which have all led to greater recognition and incidence of these conditions. Endocrinology drugs are designed to manage these diseases by regulating hormone levels, addressing glandular dysfunction, and restoring hormonal balance, thus improving health outcomes. For example, in May 2023, the National Library of Medicine reported that approximately 13 million people in the U.S. (about 4.78% of the population) suffer from undiagnosed endocrine disorders, with thyroid disease being one of the most prevalent, affecting 30% to 40% of patients treated in endocrine practices. This growing prevalence of endocrine diseases is significantly driving the demand for endocrinology drugs.
Leading companies in the endocrinology drugs market are prioritizing the development of innovative products, such as ready-to-use vials, to enhance medication administration. These pre-filled and pre-dosed containers eliminate the need for reconstitution or preparation before use. For example, in December 2022, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, introduced Levothyroxine sodium injection in ready-to-use vials with a concentration of 100 mcg/mL. This formulation is designed for immediate application, reducing the risk of preparation errors and enhancing patient safety. It ensures precise and consistent dosing, which is essential for treating conditions such as hypothyroidism and myxedema coma. Additionally, these vials improve efficiency for healthcare providers by saving time and ensuring accurate administration in urgent care scenarios.
In July 2024, AstraZeneca, a UK-based pharmaceutical company, acquired Amolyt Pharma Inc., a France-based company specializing in therapies for rare endocrine diseases. This acquisition is aimed at strengthening AstraZeneca's portfolio in rare endocrine diseases by integrating Amolyt Pharma's innovative pipeline of late-stage therapies. This move highlights the ongoing efforts by major pharmaceutical companies to expand their capabilities and offerings in the growing market for endocrinology drugs.
Major players in the endocrinology drugs market are Johnson & Johnson Inc., Merck & Co. Inc., AbbVie Inc., Bayer Aktiengesellschaft, Novartis International AG, Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Biocon Limited, Boehringer Ingelheim International GmbH, Mylan N.V., Sandoz International GmbH, Ipsen Pharma, Ferring Pharmaceuticals Inc., Endocrine Pharma Private Limited.
North America was the largest region in the endocrinology drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in endocrinology drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the endocrinology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The endocrinology drugs market consists of sales of insulin analogs, antithyroid drugs, and anti-diabetic drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Endocrinology Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on endocrinology drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for endocrinology drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The endocrinology drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Indication: Hyperthyroidism; Hypothyroidism; Diabetes; Polycystic Ovarian Syndrome; Growth Hormone Disorders; Pituitary Gland Disorders; Other Indications
2) By Therapy Area: Diabetes Drugs; Thyroid Hormone Disorder Drugs; Human Growth Hormone; Testosterone Replacement Therapy; Others Therapy Areas
3) By Distribution Channel: Hospital pharmacies; Online Pharmacies; Retail pharmacies
4) By End User: Hospitals; Ambulatory Surgical Centers; Others End Users
Subsegments:
1) By Hyperthyroidism: Antithyroid Medications; Radioactive Iodine Therapy; Beta Blockers
2) By Hypothyroidism: Levothyroxine-based Medications; Liothyronine-based Medications; Combination Hormonal Therapies
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Endocrinology Drugs Market Characteristics
3. Endocrinology Drugs Market Trends And Strategies
4. Endocrinology Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Endocrinology Drugs Growth Analysis And Strategic Analysis Framework
5.1. Global Endocrinology Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Endocrinology Drugs Market Growth Rate Analysis
5.4. Global Endocrinology Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Endocrinology Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Endocrinology Drugs Total Addressable Market (TAM)
6. Endocrinology Drugs Market Segmentation
6.1. Global Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hyperthyroidism
Hypothyroidism
Diabetes
Polycystic Ovarian Syndrome
Growth Hormone Disorders
Pituitary Gland Disorders
Other Indications
6.2. Global Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Diabetes Drugs
Thyroid Hormone Disorder Drugs
Human Growth Hormone
Testosterone Replacement Therapy
Other Therapy Areas
6.3. Global Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital pharmacies
Online Pharmacies
Retail pharmacies
6.4. Global Endocrinology Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Ambulatory Surgical Centers
Other End Users
6.5. Global Endocrinology Drugs Market, Sub-Segmentation Of Hyperthyroidism, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antithyroid Medications
Radioactive Iodine Therapy
Beta Blockers
6.6. Global Endocrinology Drugs Market, Sub-Segmentation Of Hypothyroidism, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Levothyroxine-based Medications
Liothyronine-based Medications
Combination Hormonal Therapies
6.7. Global Endocrinology Drugs Market, Sub-Segmentation Of Diabetes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Insulin Therapies
Oral Antidiabetic Drugs (OADs)
GLP-1 Receptor Agonists
SGLT-2 Inhibitors
DPP-4 Inhibitors
6.8. Global Endocrinology Drugs Market, Sub-Segmentation Of Polycystic Ovarian Syndrome (PCOS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Contraceptives
Metformin
Clomiphene Citrate
Anti-Androgens
6.9. Global Endocrinology Drugs Market, Sub-Segmentation Of Growth Hormone Disorders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Recombinant Human Growth Hormone (rhGH)
Growth Hormone Secretagogues
Growth Hormone Receptor Antagonists
6.10. Global Endocrinology Drugs Market, Sub-Segmentation Of Pituitary Gland Disorders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Somatostatin Analogs
Gonadotropins
Dopamine Agonists
6.11. Global Endocrinology Drugs Market, Sub-Segmentation Of Other Indications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adrenal Gland Disorders
Osteoporosis
Parathyroid Disorders
Male Hormonal Imbalances
7. Endocrinology Drugs Market Regional And Country Analysis
7.1. Global Endocrinology Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Endocrinology Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
